Wechselwirkungen · Efavirenz Teva
Efavirenz Teva 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 17
HOS-215309 · Präparat HOS-155418
Efavirenz: AUC: ↑ 11% (↑ 5 to ↑ 18) Cmax: ↑ 16% (↑ 6 to ↑ 26) Cmin: ↑ 13% (↑ 1 to ↑ 26) (CYP3A4 induction) The increase in efavirenz pharmacokinetic parameters is not considered clinically significant. Verapamil, felodipine, nifedipine Interaction not studied. When Dose adjustments of calcium and nicardipine efavirenz is co-administered with a channel blockers should be calcium channel blocker that is a guided by clinical response (refer substrate of the CYP3A4 enzyme, to the Summary of Product there is a potential for reduction in Characteristics for the calcium the plasma concentrations of the channel blocker). calcium channel blocker. LIPID-LOWERING MEDICINAL PRODUCTS HMG CoA Reductase Inhibitors Atorvastatin/efavirenz Atorvastatin: Cholesterol levels should be (10 mg once daily/600 mg once AUC: ↓ 43% (↓ 34 to ↓ 50) periodically monitored. Dose daily) Cmax: ↓ 12% (↓ 1 to ↓ 26) adjustment of atorvastatin may be required (refer to the Summary of 2-hydroxy atorvastatin: Product Characteristics for AUC: ↓ 35% (↓ 13 to ↓ 40) atorvastatin). No dose adjustment Cmax: ↓ 13% (↓ 0 to ↓ 23) is necessary for efavirenz.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nifedipine (HOS-086289) nicardipine (HOS-090619) atorvastatin (HOS-086304) felodipine (HOS-108908) calcium (HOS-085615) cholesterol (HOS-087961) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-03-03T18:18:00Z · SHA-256 d2c4a637bb18ba1e0c98c69218ce14671957659a5aa55fba40e74b1bf5620382 · Passage 9c1917c87e2a949443fc91072820c1baad9795f8258592f98c52407a3318bdb0 · Zeichen 48977–50882 im Abschnitt